Tysabri filed for first-line use
This article was originally published in Scrip
Executive Summary
Biogen Idec and Elan are a step closer to bringing personalised medicine to multiple sclerosis, after a fashion, as they submit applications to the US FDA and the European Medicines Agency requesting updates to the Tysabri (natalizumab) labels.